BioSenic S.A. : Information on the total number of voting rights
and shares
REGULATED INFORMATION
Information on the total number of voting
rights and shares
Mont-Saint-Guibert, Belgium, October 5,
2023, 7.00 am CEST – BIOSENIC (Euronext
Brussels and Paris: BIOS), the innovative company addressing unmet
medical needs in in the areas of innate immunity, inflammation and
organ/function repair, today announces an increase in the total
number of voting rights and shares as a result of the issuance of
new shares following the conversion of convertible bonds. The
following information is published in accordance with article 15 of
the Belgian law of 2 May 2007 on the publication of major
shareholdings in issuers whose shares are admitted to trading on
regulated market.
Total amount of share capital on August 31, 2023 |
EUR 34 500 669 |
Total number of shares with voting rights on August 31, 2023 |
137 348 141 |
Total number of new shares issued between September 1, 2023 and
September 30, 2023 |
25 833 333 |
Total amount of share capital on September 30, 2023 |
EUR 35 100 669 |
Total number of shares with voting rights on September 30,
2023 |
163 181 474 |
Total number of voting rights (denominator) on September 30,
2023 |
163 181 474 |
Total number of attributed warrants |
1 197 554 |
Total number of convertible bonds outstanding |
828 |
Total number of remaining convertible bonds commitments |
12 |
Total number of shares with voting rights that can be issued
following the exercise of the attributed warrants, remaining
convertible bonds commitments and the conversion of the convertible
bonds |
19 213 764 (1) |
(1)
- 1 197 554 shares could be issued in
case all 1 197 554 attributed warrants were exercised.
- 285 714 shares could be issued in
case all 800 convertible bonds outstanding, issued in the private
placement on 6 May 2020, were converted into shares based on
the predetermined conversion price of EUR 7.00.
- 17 730 496 shares could be issued
in case all 12 convertible bonds commitments remaining and all 28
convertible bonds outstanding of the ABO convertible bonds program
signed on 30 May 2022 were exercised and converted into shares
based on the conversion price of EUR 0.1128 (95% of the
Volume-Weighted-Averaged-Price of BioSenic's shares on September
28, 2023).
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from: (i)
the arsenic trioxide (ATO) platform (with key target indications
including Graft-versus-Host Disease (GvHD), systemic lupus
erythematosus (SLE) and systemic sclerosis (SSc)) and (ii), the
development of innovative products to meet unmet needs in
orthopedics.
Following a reverse merger in October 2022,
BioSenic combined a strategic positionings and strengths to use,
separately and combined, an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/oral ATO (OATO) with its
innovative cell therapy platform and strong IP for tissue repair
protection.
BioSenic is based in the Louvain-la-Neuve
Science Park in Mont-Saint-Guibert, Belgium. Further information is
available at http://www.biosenic.com.
About BioSenic technology
platformsBioSenic’s technology is based on two main
platforms:
1) The ATO platform, which has
been successfully developed, has immunomodulatory properties with
fundamental effects on the activated cells of the immune system.
The first effect is the increase of the cell oxidative stress in
activated B, T and other cells of the innate/adaptative immune
system to the point they will enter a cell death program
(apoptosis) and be eliminated. The second effect is potent
immunomodulatory properties on several cytokines involved in
inflammatory or autoimmune cell pathways, with return to
homeostasis. One direct application is its use in onco-immunology
to treat GvHD (Graft-versus-Host Disease) in its chronic,
established stage. cGvHD is one of the most common and clinically
significant complications affecting long-term survival of
allogeneic hematopoietic stem cell transplantation (allo-HSCT).
cGvHD is primarily mediated by the transplanted immune cells that
can lead to severe multiorgan damage. BioSenic has been successful
in a Phase II trial with its intravenous formulation, which has
orphan drug designation status by FDA and EMA. The Company is
heading towards an international Phase III confirmatory study, with
its new, IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae and the gastrointestinal tract) in an early Phase IIa
study. Systemic sclerosis is also part of the clinical pipeline of
BioSenic. This serious chronic disease badly affects skin, lungs or
vascularization, and has no actual current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a Phase II clinical protocol.
2) The allogeneic cell and gene therapy platform
developed by BioSenic, with differentiated bone marrow sourced
Mesenchymal Stromal Cells (MSCs), which can be stored at the point
of use in hospitals. ALLOB represents a unique and proprietary
approach to organ repair and specifically to bone regeneration, by
turning undifferentiated stromal cells from healthy donors into
bone-forming cells on the site of injury. ALLOB has recently been
evaluated in a randomized, double-blind, placebo-controlled Phase
IIb study in patients with high-risk tibial fractures, using its
optimized production process, after a successful first safety and
efficacy study (Phase 1/2a) on fractured long bones, with
late-delayed union. However, in June 2023, BioSenic decided to
suspend its interventional trial on fracture healing using ALLOB,
following negative results obtained for the primary endpoint in
this exploratory Phase IIb clinical trial, interpreted as a failure
of a too early cell injection, just after fracture. BioSenic is now
focusing on determining the best time to optimise the efficacy of
ALLOB (choice between early or late treatment).Note: Biosenic has
reevaluated a previous important and years-long clinical
development program. In March 2023, after the clinical
identification of distinct OA subtypes, BioSenic delivered a new
post-hoc analysis of its Phase III JTA-004 trial on knee OA,
demonstrating positive action on the most severely affected patient
subpopulation. This new post-hoc analysis drastically changes the
therapeutic profile of the combined components and allows for
better patient targeting in future clinical developments. This
leads to a next generation of JTA, off-the-shelf enhanced
viscosupplement to treat knee osteoarthritis (OA), made of a unique
combination of mammalian plasma proteins, derivatives of hyaluronic
acid (a natural component of synovial fluid in the knee) and a
third active component. JTA or some derivatives are intended to
provide effective lubrication and protection to the cartilage of
the arthritic joint and to alleviate osteoarthritic (OA) pain and
inflammation. The company, will nevertheless focus its present
R&D and clinical activities on a selective, accelerated
development of its autoimmune (ATO/OATO) platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Mont-Saint-Guibert, Belgium, October 5,
2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and
Paris: BIOS), the innovative company addressing unmet medical needs
in in the areas of innate immunity, inflammation and organ/function
repair, today announces an increase in the total number of voting
rights and shares as a result of the issuance of new shares
following the conversion of convertible bonds. The following
information is published in accordance with article 15 of the
Belgian law of 2 May 2007 on the publication of major shareholdings
in issuers whose shares are admitted to trading on regulated
market.
Total amount of share capital on August 31, 2023 |
EUR 34 500 669 |
Total number of shares with voting rights on August 31, 2023 |
137 348 141 |
Total number of new shares issued between September 1, 2023 and
September 30, 2023 |
25 833 333 |
Total amount of share capital on September 30, 2023 |
EUR 35 100 669 |
Total number of shares with voting rights on September 30,
2023 |
163 181 474 |
Total number of voting rights (denominator) on September 30,
2023 |
163 181 474 |
Total number of attributed warrants |
1 197 554 |
Total number of convertible bonds outstanding |
828 |
Total number of remaining convertible bonds commitments |
12 |
Total number of shares with voting rights that can be issued
following the exercise of the attributed warrants, remaining
convertible bonds commitments and the conversion of the convertible
bonds |
19 213 764 (1) |
(1)
- 1 197 554 shares could be issued in case all 1 197 554
attributed warrants were exercised.
- 285 714 shares could be issued in case all 800 convertible
bonds outstanding, issued in the private placement on 6 May
2020, were converted into shares based on the predetermined
conversion price of EUR 7.00.
- 17 730 496 shares could be issued in case all 12 convertible
bonds commitments remaining and all 28 convertible bonds
outstanding of the ABO convertible bonds program signed on 30 May
2022 were exercised and converted into shares based on the
conversion price of EUR 0.1128 (95% of the
Volume-Weighted-Averaged-Price of BioSenic's shares on September
28, 2023).
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from: (i)
the arsenic trioxide (ATO) platform (with key target indications
including Graft-versus-Host Disease (GvHD), systemic lupus
erythematosus (SLE) and systemic sclerosis (SSc)) and (ii), the
development of innovative products to meet unmet needs in
orthopedics.
Following a reverse merger in October 2022,
BioSenic combined a strategic positionings and strengths to use,
separately and combined, an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/oral ATO (OATO) with its
innovative cell therapy platform and strong IP for tissue repair
protection.
BioSenic is based in the Louvain-la-Neuve
Science Park in Mont-Saint-Guibert, Belgium. Further information is
available at http://www.biosenic.com.
About BioSenic technology
platformsBioSenic’s technology is based on two main
platforms:
- The ATO platform, which has been successfully developed, has
immunomodulatory properties with fundamental effects on the
activated cells of the immune system. The first effect is the
increase of the cell oxidative stress in activated B, T and other
cells of the innate/adaptative immune system to the point they will
enter a cell death program (apoptosis) and be eliminated. The
second effect is potent immunomodulatory properties on several
cytokines involved in inflammatory or autoimmune cell pathways,
with return to homeostasis. One direct application is its use in
onco-immunology to treat GvHD (Graft-versus-Host Disease) in its
chronic, established stage. cGvHD is one of the most common and
clinically significant complications affecting long-term survival
of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
cGvHD is primarily mediated by the transplanted immune cells that
can lead to severe multiorgan damage. BioSenic has been successful
in a Phase II trial with its intravenous formulation, which has
orphan drug designation status by FDA and EMA. The Company is
heading towards an international Phase III confirmatory study, with
its new, IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae and the gastrointestinal tract) in an early Phase IIa
study. Systemic sclerosis is also part of the clinical pipeline of
BioSenic. This serious chronic disease badly affects skin, lungs or
vascularization, and has no actual current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a Phase II clinical protocol.
- The allogeneic cell and gene therapy platform developed by
BioSenic, with differentiated bone marrow sourced Mesenchymal
Stromal Cells (MSCs), which can be stored at the point of use in
hospitals. ALLOB represents a unique and proprietary approach to
organ repair and specifically to bone regeneration, by turning
undifferentiated stromal cells from healthy donors into
bone-forming cells on the site of injury. ALLOB has recently been
evaluated in a randomized, double-blind, placebo-controlled Phase
IIb study in patients with high-risk tibial fractures, using its
optimized production process, after a successful first safety and
efficacy study (Phase 1/2a) on fractured long bones, with
late-delayed union. However, in June 2023, BioSenic decided to
suspend its interventional trial on fracture healing using ALLOB,
following negative results obtained for the primary endpoint in
this exploratory Phase IIb clinical trial, interpreted as a failure
of a too early cell injection, just after fracture. BioSenic is now
focusing on determining the best time to optimise the efficacy of
ALLOB (choice between early or late treatment).
Note: Biosenic has reevaluated a previous
important and years-long clinical development program. In March
2023, after the clinical identification of distinct OA subtypes,
BioSenic delivered a new post-hoc analysis of its Phase III JTA-004
trial on knee OA, demonstrating positive action on the most
severely affected patient subpopulation. This new post-hoc analysis
drastically changes the therapeutic profile of the combined
components and allows for better patient targeting in future
clinical developments. This leads to a next generation of JTA,
off-the-shelf enhanced viscosupplement to treat knee osteoarthritis
(OA), made of a unique combination of mammalian plasma proteins,
derivatives of hyaluronic acid (a natural component of synovial
fluid in the knee) and a third active component. JTA or some
derivatives are intended to provide effective lubrication and
protection to the cartilage of the arthritic joint and to alleviate
osteoarthritic (OA) pain and inflammation. The company, will
nevertheless focus its present R&D and clinical activities on a
selective, accelerated development of its autoimmune (ATO/OATO)
platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect the Company or, as appropriate, the Company
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biosenic (EU:BIOS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biosenic (EU:BIOS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024